Medical Management of Acute Venous Thromboembolism

Abstract

Venous thromboembolic disease (VTE) is a major cause of morbidity and mortality worldwide, consisting of both deep vein thrombosis (DVT) and pulmonary embolism (PE). Therapeutic anticoagulation is the primary treatment for acute VTE with the therapeutic goals of reducing proximal DVT embolization, inhibiting propagation or formation of new or recurrent VTE, and reducing mortality in patients with PE. Direct oral anticoagulants (DOACs) are now considered first-line therapy for most patients with acute VTE, though parenteral therapy and vitamin K antagonist (VKAs) remain as the preferred option in select patient groups. This study practically summarizes the medical management of acute VTE for interventionalists, focusing on the choice of agent amongst common pharmacologic therapies as well as the optimal duration of therapy based on risk factors for recurrent VTE.

Keywords

venous thromboembolism - medical management - anticoagulation - direct oral anticoagulants - heparin - interventional radiology

Publikationsverlauf

Artikel online veröffentlicht:
02. Dezember 2025

• References

• 1 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (06) 585-593
• 2 Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28 (03) 370-372
• 3 Fernandes T, Planquette B, Sanchez O, Morris T. From acute to chronic thromboembolic disease. Ann Am Thorac Soc 2016; 13 (Suppl. 03) S207-S214
• 4 Hirsh J, Anand SS, Halperin JL, Fuster V. American Heart Association. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103 (24) 2994-3018
• 5 Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA 2022; 328 (13) 1336-1345
• 6 Cox C, Roberts LN. Basics of diagnosis and treatment of venous thromboembolism. J Thromb Haemost 2025; 23 (04) 1185-1202
• 7 Segal JB, Brotman DJ, Necochea AJ. et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301 (23) 2472-2485
• 8 Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and cytoprotective pathways. Int J Hematol 2012; 95 (04) 333-345
• 9 Doyle DJ, Turpie AG, Hirsh J. et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med 1987; 107 (04) 441-445
• 10 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1 (7138) 1309-1312
• 11 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301 (16) 855-858
• 12 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 13 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021. Chest 2024; 166 (02) 388-404
• 14 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) e545-e608
• 15 Piazza G, Bikdeli B, Pandey AK. et al; HI-PRO Trial Investigators. Apixaban for extended treatment of provoked venous thromboembolism. N Engl J Med 2025; 393 (12) 1166-1176
• 16 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
• 17 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
• 18 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
• 19 Khairani CD, Bejjani A, Piazza G. et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol 2023; 81 (01) 16-30
• 20 Diesveld MME, Pijnenburg DWMJ, Weersink RA. et al. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. Eur J Clin Pharmacol 2024; 80 (06) 797-812
• 21 Kraaijpoel N, Di Nisio M, Mulder FI. et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 2018; 118 (08) 1439-1449
• 22 Tomaselli GF, Mahaffey KW, Cuker A. et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76 (05) 594-622
• 23 Tanaka KA, Shettar S, Vandyck K, Shea SM, Abuelkasem E. Roles of four-factor prothrombin complex concentrate in the management of critical bleeding. Transfus Med Rev 2021; 35 (04) 96-103
• 24 Connolly SJ, Sharma M, Cohen AT. et al; ANNEXA-I Investigators. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 2024; 390 (19) 1745-1755
• 25 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 suppl): e24S-e43S
• 26 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 suppl): 454S-545S
• 27 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (09) 673-684
• 28 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
• 29 Bijsterveld NR, Vink R, van Aken BE. et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124 (05) 653-658
• 30 Corbonnois G, Martin M, Hacquard M. et al. Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats. Thromb Haemost 2013; 109 (03) 560-563
• 31 Rodger MA, Le Gal G, Anderson DR. et al; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356: j1065
• 32 Couturaud F, Schmidt J, Sanchez O. et al; RENOVE Investigators. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet 2025; 405 (10480): 725-735
• 33 Xiao N, Genet M, Khaja M, Desai KR. Antithrombotic therapy after deep venous intervention. Semin Intervent Radiol 2022; 39 (04) 357-363
• 34 Kishore S, Khaja MS, Thornburg B. et al. Antithrombotic therapy after venous interventions: AJR expert panel narrative review. AJR Am J Roentgenol 2022; 219 (02) 175-187
• 35 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following venous stenting: international delphi consensus. Eur J Vasc Endovasc Surg 2018; 55 (04) 537-544
• 36 Barco S, Jalaie H, Sebastian T. et al. Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: the multicenter, multinational, randomized, open-label ARIVA trial. Circulation 2025; 151 (12) 835-846
• 37 Notten P, Ten Cate H, Ten Cate-Hoek AJ. Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: a systematic review. J Thromb Haemost 2021; 19 (03) 753-796